glp-1 for iih glp 1 Recurrent Idiopathic Intracranial Hypertension–Related Papilledema After Abrupt Discontinuation of Semaglutide: JNO Article: https://bit.ly/JNO_recurr_IIH_GLP1RA #brain #eye #vision #research #Neurology #NeuroOphth #Ophthalmology #Medicine NeuroOp Guru: Stopping GLP-1 therapy

This dose delivers results comparable to the maximum approved dose of Semaglutide (Wegovy 2.4mg), which produces 14.9% weight loss but with significantly higher nausea at 44%

Ageing causes a decline in the production of cell energy

That means 38% of requests were denied on first submission

Considerable potential A meta-analysis of randomized controlled trials, published last month in Annals of Internal Medicine , showed GLP-1 receptor agonists did not affect risk for multiple malignancies including colorectal cancer among adults with type 2 diabetes, or those with overweight or obesity

Months 2 through 3: dose escalation effects Each dose increase may bring a mild recurrence of initial side effects, typically lasting three to five days

Outcomes In our analysis of nine studies comparing GLP-1RAs to placebo for WL following bariatric surgery, we found no significant differences between the two groups (SMD = 0.56, 95% CI -0.19 to 1.30) (Fig